相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Pharmacists have evolved from traditional dispensing roles to comprehensive patient management in cancer care, particularly with novel therapies like CAR-T cell therapy and bispecific antibodies. - Patient selection has become a critical pharmacist responsibility, as not every patient qualifies for these advanced therapies and multiple treatment options require careful evaluation. - Pharmacists now proactively manage toxicities by monitoring lab results and patient symptoms, enabling dose adjustments and prophylactic interventions to maintain treatment continuity. - The expanded role includes value-based care participation, medication adherence monitoring, and close collaboration with multidisciplinary teams to optimize patient outcomes.
- Stem cell transplantation remains a cornerstone treatment for multiple myeloma despite the emergence of CAR T-cell therapy and bispecific antibodies, offering a cost-effective "one and done" approach that has proven efficacy over four decades. - Novel therapies like CAR T and bispecifics face adoption challenges including hospitalization requirements, cytokine release syndrome management, and significantly higher costs, with CAR T therapy costing up to half a million dollars. - Experts emphasize that these therapies should complement rather than compete with each other, as multiple myeloma remains incurable and requires sequential treatment approaches to maximize overall survival. - The widespread adoption of bispecific therapies is limited by REMS requirements and the need for inpatient step-up dosing due to cytokine release syndrome risks, particularly affecting rural and community settings.
• The FDA has approved Neurelis' VALTOCO (diazepam nasal spray) for treating seizure clusters in patients as young as 2 years old, expanding its previous indication to include younger children. • Clinical trials demonstrated VALTOCO's safety and efficacy in children aged 2-5, with 31 of 35 enrolled patients completing the 180-day safety period and no treatment-related serious adverse events reported. • The nasal spray formulation provides a significant alternative to rectal diazepam, addressing a major unmet need for caregivers managing seizures in young children.
- New evidence review reveals resistance exercise significantly improves sleep quality in seniors, outperforming aerobic and combination exercises with a 5.7-point average increase in sleep quality scores. - Up to 50% of older adults globally experience sleeping difficulties, with insomnia increasing risks for heart disease, cognitive impairment, dementia, and falls. - Researchers analyzed data from 25 clinical trials involving nearly 2,200 older adults, finding that strength training offers the most significant benefits for treating age-related insomnia.
- A 33-year-old patient with acute myeloid leukemia (AML) achieved remission through a clinical trial using IDHIFA, an oral medication targeting the IDH2 mutation. - The patient, who initially underwent intensive remission induction therapy with chemotherapy, opted for the IDHIFA trial as an alternative to a bone marrow transplant. - IDHIFA works by turning off the mutated IDH2 gene, restoring normal cell function and offering a targeted approach to treating AML in patients with this specific mutation. - The patient experienced minimal side effects and has returned to work and normal activities, highlighting the potential of targeted gene therapy in leukemia treatment.
